BIOLIN.RX S.ADR/ IL-,01 Forum: Community User: AdlerX8

ich hab eigentlich gedacht, dass die daten ganz gut seien, aber ich versteh halt nicht viel von Bios :) Morgen gibt es einen Vortrag von Bioline auf der Esmo in München. ich warte ab, denn die Pipeline kommt mir ganz anständig vor

So berauschend waren die Daten wohl nicht oder warum ist es runterfallen ?

Bei Bio's braucht man sehr gute Nerven

Background Current treatment options for PDAC patients are limited by poor survival and toxicity. Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis are successful in treating several cancer types; however, PDAC remains refractory. In PDAC mouse models, blockade of the CXCR4/CXCL12 axis promotes tumor infiltration of T cells and synergistic anti-tumor effects when combined with anti-PD-1/anti-PD-L1. We have shown that the high affinity CXCR4 antagonist BL-8040 given as monotherapy promoted infiltration of T cells into metastatic liver lesions in PDAC patients. Here, we report efficacy data from this ongoing Phase 2a clinical trial designed to assess the ability of BL-8040 to enhance responsiveness to the anti-PD-1 ICI Pembrolizumab in patients with metastatic PDAC. Methods Phase 2a study consisting of 5 days BL-8040 monotherapy followed by repeated 3-week cycles of Pembrolizumab Q3W in combination with BL-8040 TIW for up to two years. Eligibility criteria included second line (2L) or higher metastatic PDAC with measurable disease by RECIST1.1. Results As of May 2018, 37 patients were enrolled in the study of which 29 were evaluable (i.e. received at least one dose of combination and have a post baseline CT) and 17 received one previous treatment line (2L). Response by RECIST1.1 for the evaluable population showed 1 subject (3.4%) with partial response and 9 (31%) with stable disease, yielding 34.5% (10 subjects) with disease control. Mismatch repair status is available for 5 patients with disease control, and all are microsatellite stable (MSS). The most common adverse event was injection site reaction (mild to moderate). Median overall survival (OS) in the entire population and in the 2L subgroup is 3.4 and 7.5 months, respectively, with 6-month survival rates of 34.9% and 50.4%, respectively. Conclusions PDAC treatment with BL-8040 and Pembrolizumab is safe, tolerable and shows promising OS, particularly in the 2L subgroup of patients that demonstrated median OS of 7.5 months. This is in comparison to the 6.1 months OS of Onivyde + 5-FU/Leucovorin (approved 2L chemotherapy; NAPOLI-1 trial). Furthermore, these results were seen in MSS subjects, resistant to ICIs as single agents.

Das hoffe ich auch

Ich denke aber nicht, dass da schon News durchgesickert sind. Ich hoffe, dass da nur stop loss abgefischt wurden ✌

Jetzt geht es aber abwärts

Schaut echt gut aus, aber am Freitag wissen wir mehr

Na das geht doch schon mal gut los und lässt für die nächsten Tage hoffen. ✌

Vielleicht steige ich vorher nochmal ein

@FCINGO @Moma seid ihr hier dabei?

so langsam läuft's. vom 19-23. Oktober ist biolinerx auf der esmo in München. Dazu kommen am 19. Oktober auch Phase 2 Daten

Bin mit einer kleinen Position dabei

Na Moma hier passiert nicht viel was ? ✌

Sehr gut!! War meine erste Idee!! Und wenn Vor Ergebnisse gut sind,werden die Haupt Ergebnisse schlecht?? Neeeein.. Sorrento hat gerade mega News!!

Erinnert mich an Inotek hast sie auch bei 89 Cent empfohlen.